Clinical Trials Logo

Heart Failure NYHA Class II clinical trials

View clinical trials related to Heart Failure NYHA Class II.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06306573 Enrolling by invitation - Clinical trials for Heart Failure NYHA Class III

CardioMEMS HF System Real-World Evidence Post-Approval Study

Start date: December 15, 2022
Phase:
Study type: Observational

The purpose of this post-approval study (PAS) is to evaluate the long-term safety and effectiveness of the CardioMEMS™ HF System using real-world evidence (RWE) methods.

NCT ID: NCT05885607 Enrolling by invitation - Heart Failure Clinical Trials

Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure

EMAS-HF
Start date: June 27, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn about SGLT2 inhibition medications in patients with symptomatic heart failure who are clinically prescribed FDA-approved SGLT2 inhibitors. The main question it aims to answer is: - What are the impacts of SGLT2 inhibition on systemic metabolomic and proteomic profiles? Participants will be asked to do the following before and after being prescribed a SGLT2i. - Six-minute walk testd - Calf MRI with plantar flexion exercise - Blood sample collection